Health Care Equipment

Co-Diagnostics

Co-Diagnostics released FY2026 Q1 earnings on May 14 After-Market (EST), actual revenue USD 145.95 K (forecast USD 163.5 K), actual EPS USD -4.0599 (forecast USD -3.75)

Co-Diagnostics Reports Q1 FY2026 Results: Revenue and Earnings Miss Expectations

Co-Diagnostics to Release FY2026 Q1 Earnings on May 14 After-Market EST, Forecast Revenue USD 163.5 K, EPS USD -3.75

Co-Diagnostics released FY2025 Q4 earnings on March 31 After-Market (EST), actual revenue USD 263.92 K (forecast USD 126 K), actual EPS USD -13.6674 (forecast USD -3.6)

Co-Diagnostics released FY2025 earnings on March 31 After-Market EST, actual revenue USD 622.49 K (forecast USD 484.5 K), actual EPS USD -35.2548 (forecast USD -21)

Co-Diagnostics to Release FY2025 Q4 Earnings on March 31 After-Market EST, Forecast Revenue USD 126K, EPS USD -3.6

Maxim Group Analyst Maintains Buy Rating on Co-Diagnostics

Co-Diagnostic released FY2025 Q3 earnings on November 13 After-Market (EST), actual revenue USD 145.38 K (forecast USD 300 K), actual EPS USD -0.16 (forecast USD -0.19)

Co-Diagnostic released FY2025 9 Months earnings on November 13 After-Market (EST), actual revenue USD 358.57K, actual EPS USD -19.0043

Co-Diagnostics Completes Registered Direct Offering Raising $3.8 Million

Co-Diagnostic to Release FY2025 Q3 Earnings on November 13 After-Market EST, Forecast Revenue USD 150K, EPS USD -0.175

Co-Diagnostics Inc. hires Maxim Group to explore strategic options for its Indian joint venture

Co-Diagnostics Plans Virtual Fireside Chat

Co-Diagnostics, Inc. To Attend 2025 Maxim Growth Summit and Engage with Investors

Co-Diagnostic released FY2025 Semi-Annual earnings on August 14 After-Market EST, actual revenue USD 213.19K, actual EPS USD -0.4698

Co-Diagnostic released FY2025 Q2 earnings on August 14 After-Market EST, actual revenue USD 162.91 K (forecast USD 300 K), actual EPS USD -7.0043 (forecast USD -7.5)

Co-Diagnostic to Release FY2025 Q2 Earnings on August 14 After-Market EST, Forecast Revenue USD 300K, EPS USD -0.25

CoDiagnostics Q4 Exceeds Earnings and Revenue Expectations

Co-Diagnostic released FY2025 Q1 earnings on May 8 After-Market EST, actual revenue USD 50.28 K (forecast USD 187.5 K), actual EPS USD -7.1999 (forecast USD -8.1)

Co-Diagnostic Expected EPS of -0.33 USD

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up

CODX

SBIO

LABU

Co-Diagnostics Inc. (CODX) has developed a Bundibugyo virus assay for rapid detection amid escalating Ebola outbreak alerts. Following WHO's emergency declaration, the company emphasizes the importance of decentralized diagnostics and rapid PCR testing. CEO Dwight Egan highlighted the need for quick mobilization in response to infectious diseases, shaped by lessons from COVID-19. The company is prepared for collaboration on future assay development. CODX shares are currently trading at $2.07, up 51.09%.

nasdaq

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Nasdaq

CLDX

GLUC

ANVS

In Tuesday's after-market session, Co-Diagnostics shares surged 20.8% to $2.38, while Celldex Therapeutics rose 16.05% to $34.99. Other gainers included INVO Fertility (+13.28%) and Evaxion (+7.78%). Conversely, Annovis Bio fell 18.1% to $1.59, with GlucoTrack down 17.56%. Wellgistics Health and NexGel also saw declines of 10.72% and 10.41%, respectively. Most companies reported Q1 earnings recently.

benzinga_article

Celldex Therap

Glucose Health, Inc.

Annovis Bio

iShares US Pharma

Health Care Select Sector SPDR

SPDR S&P Health Equip

iShares Global Healthcare

INVO Fertility

Evaxion A/S

NeuroOne Medical Tech

Biorestorative Therapies

GlucoTrack

Wellgistics Health

Nexgel

AIM ImmunoTech

Icecure Medical

NEXGEL INC C/WTS 27/12/2026 (TO PUR COM)

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

12 Health Care Stocks Moving In Tuesday's After-Market Session

AMIX

MTVA

On Tuesday, Med Pharmaceuticals (NASDAQ:INM) saw a 127% increase to $1.54, while MetaVia (NASDAQ:MTVA) rose 58.54% to $1.76. Other gainers included Co-Diagnostics (NASDAQ:CODX) up 41.6% and Edesa Biotech (NASDAQ:EDSA) up 32.11%. Conversely, WORK Medical Tech Gr (NASDAQ:WOK) dropped 39% to $0.23, and Autonomix Medical (NASDAQ:AMIX) fell 25.43%. AIM ImmunoTech (AMEX:AIM) declined 18.02% to $0.33.

Autonomix Medical

WORK Medical Tech

Edesa Biotech

iShares US Medical Devices

Invesco Nasdaq Biotechnology ETF

Adial Pharmaceuticals

Virax Biolabs

Akanda

Psyence Biomedical

Quantum Cyber NV

PSYENCE BIOMEDICAL LTD C/WTS 25/01/2029(TO PUR COM)

Mainz Biomed NV

12 Health Care Stocks Moving In Tuesday's Intraday Session

Co-Diagnostics, Inc. has developed an assay strategy for the Bundibugyo virus (BDBV) following the recent Ebola outbreak in the Democratic Republic of the Congo and Uganda. The company emphasizes the importance of rapid PCR diagnostics and real-time situational awareness in managing infectious disease threats. With the WHO declaring the outbreak a public health emergency, Co-Diagnostics aims to collaborate with health authorities to ensure preparedness and swift response capabilities.

prnewswire

09:00 ETCo-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert

Earnings Watch

Co-Diagnostics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 145.95 K

Co-Diagnostics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 145.95 K

Co-Diagnostics(CODX.US)